Admaius Capital Partners and Parkville Pharmaceuticals Founders Exit to Adenia Partners in Majority Stake Sale
Cairo, Egypt – January 27, 2026 — Admaius Capital Partners and Parkville Pharmaceuticals founders Dr. Sherif Bassiouny and Dr. Mahmoud Farrag announced definitive agreements to sell a majority stake in Parkville Pharmaceuticals to Adenia Partners. The transaction marks the first exit from Admaius’ Virunga Africa Fund 1 and delivers attractive dollar returns to investors after a two-year hold period. The deal highlights private equity resilience in Egypt’s challenging macroeconomic environment.
Transaction Details
Admaius Capital Partners initially invested alongside Parkville’s founders in November 2023. Cairo-headquartered Parkville, founded in 2008, specializes in cosmeceuticals, skincare, haircare, nutraceuticals, and pharmaceutical products under brands including StarVille, StrongVille, and Glamy Lab. The company operates a production facility in Alexandria and exports regionally across North Africa and the Middle East.
During Admaius’ ownership, Parkville achieved growth through enhanced product development, strengthened governance frameworks, manufacturing improvements, and expanded e-commerce capabilities despite currency devaluations and inflationary pressures. Financial terms of the transaction remain undisclosed. The deal is subject to customary regulatory approvals.
Stakeholder Perspectives
“We are incredibly proud of the work we have done alongside Parkville’s founders and management over the past two years. This investment reflects Admaius’ ability to execute in complex environments, partner closely with exceptional local teams, and help build market-leading businesses. The dollar returns to our investors are very attractive and demonstrate what is possible when strong market positioning, drive and focus combine with superior execution. This is the first exit in our current fund and underpins its strong performance.”
— Marlon Chigwende, Managing Partner at Admaius Capital Partners
Why it matters: The statement underscores Admaius’ operational track record in frontier markets and signals strong performance metrics for the fund’s remaining portfolio companies.
“Our work with Parkville demonstrates Admaius’ execution capabilities on the ground in Egypt. Together with the management team, we focused on strengthening operations, governance, and scalability while navigating a challenging macroeconomic environment. We are proud of the outcome and of the value created through a hands-on, partnership-driven approach.”
— Ahmed Rady, Managing Director at Admaius Capital Partners
Why it matters: The perspective highlights operational value creation as a core driver of returns in emerging markets facing structural economic headwinds.
Industry Context
Egypt’s cosmeceutical and pharmaceutical sectors are experiencing accelerated growth driven by rising consumer demand and demographic expansion. Parkville has established itself as a local market leader competing effectively against international brands. Private equity capital increasingly targets African healthcare and consumer sectors for attractive growth profiles and development impact potential.
The transaction connects Kigali-based Admaius Capital Partners, which maintains a Cairo office, with Adenia Partners, which has raised over $1 billion in capital commitments. The deal exemplifies rapid investment cycles and cross-border capital flows within Africa’s private equity ecosystem, particularly in sectors demonstrating resilience to macroeconomic volatility.
Outlook
Adenia Partners’ investment is expected to accelerate Parkville’s regional scaling, support job creation, and advance ESG alignment objectives. The transaction reinforces private equity’s role in driving operational transformation and growth capital deployment across Egyptian and North African healthcare and consumer markets.
Sources: Zawya, Admaius Capital Partners, Business Wire, The New Times
